Lupin appoints Dr. Fabrice Egros as President, Corporate Development & Growth Markets

#Lupin #Appointments #LeadershipChange

Source: Lupin

“With Fabrice’s leadership and demonstrated success in growing Lupin’s business through both organic and inorganic initiatives, we are well positioned to deliver on our growth aspirations. We thank Alan for his contribution to our organization and wish him well for the future.” - Vinita Gupta, CEO, Lupin

February 2022 : Global pharma major, Lupin Limited (Lupin) has recently announced changes to its executive team with Dr. Fabrice Egros assuming responsibilities as President, Corporate Development and Growth Markets. Dr. Egros takes over the Corporate Development role from Alan Butcher departing from the Company on February 28, 2022. Dr. Egros will lead the development and execution of the Company’s inorganic growth strategy, including mergers and acquisitions, business development, in-licensing arrangements, and related matters. He will continue to lead business in LATAM and Asia regions in this new role. “We are very pleased to announce Fabrice taking over responsibilities for Corporate Development in addition to the Growth Markets business. With Fabrice’s leadership and demonstrated success in growing Lupin’s business through both organic and inorganic initiatives, we are well positioned to deliver on our growth aspirations. We thank Alan for his contribution to our organization and wish him well for the future,” said Vinita Gupta, CEO, Lupin.

For the past over six years, Dr. Egros has played an integral role in Lupin, leading businesses across both Growth and Developed markets. His extensive cross-border experience as well as successful experience with acquisitions, divestitures, joint ventures and partnerships will be an asset to Lupin in this new role.